



Via Express Mail No.: EV 582 626 101 US Mailing Date: September 28, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ashkenazi et al.	Docket No.:	39780-2630P1C21
Serial No.:	09/978,423	Group Art Unit:	1648
Filing Date:	October 16, 2001	Examiner:	Le, Emily M.
For:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME		

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form Supplemental PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☐ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ **Fee Authorization.** The Commissioner is hereby authorized to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-2630P1C21)**.


Respectfully submitted,

Dated: September 28, 2005

By: Leslie Mooi
Leslie Mooi (Reg. No. 37,047)

HELLER EHRMAN LLP (Customer No. 09157/35489)
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000 /Facsimile: (650) 324-0638

SV 2156428 v1



Form PTO-1449 INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	Attorney's Docket No. 39780-2630P1C21	Application Serial No. 09/978,423
	Applicant(s) Ashkenazi <i>et al.</i>	
	Filing Date: October 16, 2001	Group Art Unit: 1648

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	08-20-1996	5,547,862	Meador <i>et al.</i>			
	2.	11-14-2002	2002/0168713	Curtis, Rory A.J.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	3.	Grifman, M. <i>et al.</i> , "Functional Redundancy of Acetylcholinesterase and Neuroligin in Mammalian Neuritogenesis," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp 13935-13940, 1998.
	4.	Sequence alignment of KIAA1260 protein of Nagase <i>et al.</i> with SEQ ID NO: 375.
	5.	Sequence alignment of SEQ ID NO: 2 of Curtis <i>et al.</i> with SEQ ID NO: 375.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2156428 v1	